Tuesday brunch: the ketamine backlash continues

Plus a member of the FDA Ad-Comm explains why she said no to Lykos

Welcome to another Tuesday Brunch, EI’s weekly round-up of interesting psychedelic and ecstatic news from around the internet.

Mainstream news coverage of ketamine is not good at the moment, in the wake of the DEA and Justice Department’s purported crackdown on overprescribing doctors. There’s critical coverage in the Mail, ITV, CNN, and even on Bill Maher’s late night show. Many media outlets are taking potshots at Mindbloom and other ketamine telehealth providers like Nue Life and Joyous.

In addition, a member of the FDA advisory committee speaks out about why she rejected Lykos’ FDA application for MDMA therapy – she said it was the allegations of clinical trial misconduct that raised doubts for her – and I speak to the maker of that AI video about Trump taking ayahuasca, to ask how he made it.

All that and more after the paywall.